QPPV.COM KNOWLEDGE ASSESSMENT

Alemtuzumab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Alemtuzumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient develops a serious autoimmune disorder several months after completing an alemtuzumab treatment course. Which pharmacovigilance interpretation is most appropriate?

The event is unrelated because the infusion has already ended. The event should automatically be attributed to the last infusion. The delayed timing remains clinically relevant because biological consequences can persist beyond administration. Only events occurring during the infusion can be assessed for causality.

Question 2 of 10 Which statement best reflects the role of a targeted follow-up questionnaire in alemtuzumab pharmacovigilance?

Sending the questionnaire completes the medical assessment even if no returned information is reviewed. The questionnaire should be identical for every adverse event to ensure consistency. The tool is useful only if the returned information is medically reviewed and incorporated into the case assessment. A questionnaire can replace the need to document competing causes.

Question 3 of 10 Why should autoimmune thyroid disease, immune thrombocytopenia, renal autoimmunity, serious infection and infusion-associated reactions not be combined into one undifferentiated 'immune-related' category?

They require different follow-up questions, case definitions and aggregate analyses. Only infusion-associated reactions are relevant to pharmacovigilance. Broad categories are always required by EU pharmacovigilance legislation. These events cannot occur in the same treated population.

Question 4 of 10 What is the appropriate pharmacovigilance position on rechallenge with alemtuzumab?

Rechallenge should routinely be performed to confirm causality. Rechallenge can add evidence if it occurs in routine care, but should not be deliberately manufactured when clinically inappropriate. Rechallenge has no evidentiary value under any circumstances. A rechallenge is required before a serious event can be reported.

Question 5 of 10 Which statement best explains why alemtuzumab's mechanism is useful in pharmacovigilance but cannot by itself establish causality?

Binding to CD52 proves that every immune-mediated event after treatment was caused by alemtuzumab. The mechanism identifies biologically plausible event patterns, but chronology, objective findings and alternative causes must also be assessed. The mechanism is relevant only to clinical efficacy and should not be considered during adverse-event assessment. Because alemtuzumab causes lymphocyte depletion, all subsequent events should be classified as expected.

Question 6 of 10 What was the principal pharmacovigilance significance of the EU safety review conducted from 2019 to 2020?

It removed all restrictions on alemtuzumab use. It restricted use and strengthened risk-minimisation measures addressing rare but serious cardiovascular, bleeding and immune-mediated reactions. It established that all post-treatment events were caused by lymphocyte depletion. It changed alemtuzumab from a monoclonal antibody into a small molecule.

Question 7 of 10 If the number of exposed patients is uncertain, how should an apparent adverse-event rate be presented?

Provide a precise rate using an assumed denominator without qualification. Suppress all analysis until the denominator is perfect. State the denominator limitation and avoid presenting false precision. Replace the rate with a preferred-term count and describe it as incidence.

Question 8 of 10 Which statement best describes the purpose of benefit-risk evaluation for alemtuzumab?

To determine whether any adverse events exist, regardless of population or treatment context. To assess whether the evolving balance remains acceptable for the authorised population under applicable conditions of use. To focus exclusively on serious adverse reactions and ignore treatment benefit. To compare the product only with other monoclonal antibodies.

Question 9 of 10 Which approach is most appropriate for aggregate signal review of alemtuzumab?

Pool all cases regardless of treatment phase, indication, prior therapy or comorbidity. Use preferred-term counts alone because medical review can introduce bias. Retain clinically meaningful strata and use medically defensible event groupings with a documented case definition. Exclude cases with uncertain causality before calculating any pattern.

Question 10 of 10 Which exposure information is most important for reconstructing an alemtuzumab case in a way that supports both clinical assessment and possible product-quality investigation?

Only the active-substance name and the patient's age The exact product and presentation, route, dose, administration date, treatment phase and batch where available Only the date on which the adverse event was reported The patient's preferred method of follow-up communication

Alemtuzumab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings